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a b s t r a c t
Background: There is little information regarding appropriate therapies for coronary artery disease (CAD)
patients with implantable devices – such as implantable cardioverter-deﬁbrillators (ICDs), cardiac
resynchronization therapy devices (CRT-Ds) and cardiac resynchronization therapy pacemaker (CRT-P)
devices – in Japan. To address this lack of information, we have launched the Japan Implantable Devices
in Coronary Artery Disease (JID-CAD) study.
Methods: This study has been designed as a prospective, multicenter, non-randomized and observational
investigation. All patients will be followed up every six months over a two-year period. The primary
endpoint will be the administration of appropriate device therapy. Secondary endpoints include
administration of inappropriate therapy, death, hospitalization, or cardiovascular events.
Conclusion: In this report, we discuss the current clinical situation of appropriate therapy, and how it is
inﬂuenced by catheter ablation and revascularization therapy in patients with CAD.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Implantable cardiac deﬁbrillator devices, such as implantable
cardiac cardioverter-deﬁbrillators (ICDs) and cardiac resynchroniza-
tion therapy with ICD (CRT-D), comprise the therapy of choice for
prevention of sudden cardiac death, and are used widely for both
primary and secondary prophylaxis [1–3]. ICDs were ﬁrst approved
by the Japanese government more than 20 years ago; they are widely
used, and are considered the most effective therapy for lethal
ventricular tachyarrhythmia, both in Japan and globally. The Japan
Cardiac Device Treatment Registry (JCDTR), run by the Japanese
Heart Rhythm Society (JHRS), founded in 2006, records the current
clinical situation of cardiac implantable deﬁbrillator devices [4,5].
Mortality rates from coronary artery disease (CAD) are between
10% and 12.5% lower in Japanese patients than in Eastern and
Northern European cohorts, and are approximately 20% lower than
in Western Europeans and North Americans [6]. The estimated
incidence of acute myocardial infarction in Japan was reported as
3060 per 100,000 males and 1020 per 100,000 females,
between 1990 and 2000 [7]. Mortality rates are expected to rise
in Japan owing to changes in diet and lifestyle [8]. In fact, the
incidence CAD was relatively stable until 2000 [9], though recent
research suggests that rates have been increasing since then [10].
The rate of CAD in Japanese patients implanted with ICDs is
lower than in Western countries; the percentage of devices
implanted for primary prevention is also markedly lower
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[4,11,12]. The prognosis of Japanese patients with CAD was
hypothesized to improve following application of MADIT-II criteria
[1,13–15]; however, some investigators have suggested that
application of MADIT-II criteria to Japanese patients may be
inappropriate [13]. Nonetheless, patients with CAD and implanted
devices for primary prevention in Japan had more frequent
appropriate therapy and worse prognosis than expected
[16]. One possible factor in these unexpected results may be the
implantation of cardiac implantable devices in patients with
relatively severe prognoses, or late-stage congestive heart
failure [16].
The indications for cardiac implantable devices have been
adapted in line with the advancement of therapy for CAD and
lethal ventricular arrhythmia. However, the relationship between
indications and expected prognosis has not been well established
in Japanese CAD patients, and use of cardiac implantable devices is
currently inﬂuenced by the availability of intervention therapy for
CAD and lethal arrhythmia.
The purpose of this study is to clarify the current status of
cardiac implantable deﬁbrillation therapy and prognosis in Japa-
nese patients with CAD, and to evaluate the inﬂuence of CAD-
speciﬁc therapies – including intervention and stenting – and
lethal ventricular tachyarrhythmias on the choice of deﬁbrillation
therapy. The study will be prospective, multicenter, observational
and non-randomized in nature. We anticipate that the data
collected will facilitate more effective decision-making in the
treatment of ventricular arrhythmias and CAD therapy, and the
institution of more appropriate guidelines for the implantation of
deﬁbrillation devices in Japan.
2. Material and methods
2.1. Participating centers
Approximately 60 centers across Japan will participate in this
study. After obtaining written informed consent, patients over the
age of 20, with CAD and cardiac implantable devices (ICD, CRT-D),
or cardiac resynchronization therapy with pacing (CRT-P), will be
enrolled. Other doctors or centers may also participate in this
study with the permission of the Central Committee of JID-CAD.
2.2. Patients
Criteria for enrollment were as follows: (1) ICD/CRT-D/CR-P
newly implanted in accordance with the guideline on non-
pharmacological therapy for cardiac arrhythmias, published by
the Japanese Circulation Society in 2011 [17]; (2) CAD including
myocardial infarction, effort angina and vasospastic angina; and
(3) age Z20 years, regardless of gender.
Table 1
Parameters to be recorded at time of enrollment.
Information on implantation
1. Name of institute and date of registration
2. Age and gender of the patient
3. Date of implantation
4. Names of operators
5. Purpose of implantation (primary or secondary prevention)
6. Implantation indications based on Japanese guidelines from 2011a
7. Name and manufacturer of the implanted device
8. Mode of implanted device [single chamber with lead placed only at the ventricle(s) or dual chamber with lead placed at the atrium and ventricle(s)]
9. Mode on setting at the implantation (e.g. zone settings, VF sensing criteria, VT sensing criteria, monitor only setting)
10. Implanted leads (atrium, ventricle 1, ventricle 2)
11. Deﬁbrillation threshold and minimum energy for deﬁbrillation
12. Complications
Patient characteristics
1. Height and body weight at time implantation
2. Aspects related to coronary artery disease (interval since last myocardial infarction, data relating to ﬁrst and latest myocardial infarction, if known)
Type of angina pectoris (effort, vasospastic, both)
Location of the diseased coronary vessel in patients with prior myocardial infarction
3. Cardiac disease other than coronary artery disease
4. History of atrial ﬁbrillation/ﬂutter
5. Disease other than cardiac disease
6. New York Heart Association (NYHA) classiﬁcation
7. Left ventricular ejection fraction (LVEF), method of assessment
8. Coronary angiography (CAG) ﬁndings at time of registration, and ischemic area if coronary artery bypass graft (CABG) has been performed
9. History of coronary artery reconstruction [percutaneous coronary intervention (PCI), CABG]
10. ECG (rhythm, QRS duration before and after implantation, and chest radiograph ﬁndings)
11. History of non-sustained ventricular tachycardia (NSVT)
12. Therapy and related data (most recent, if performed more than once) for NSVT/VT (catheter ablation, cardiac surgery)
13. Dyssynchrony (degree, method)
14. Signal-averaged ECG
15. Microvolt T wave alternans
16. Electrophysiologic study
17. Holter ECG
18. Blood and laboratory data
Medication given at implantation
1. Antiarrhythmic drugs
2. Diuretics (ACE inhibitors or ARBs)
3. Antiplatelet or anticoagulant therapy
At implantation
1. Wearable cardioverter-deﬁbrillator (WCD)
2. Hemodialysis
a Refer to [17].
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2.3. Data collection
Parameters to be recorded at the time of enrollment are shown
in Table 1; those to be recorded during follow-up, in Table 2.
The data collection methods will follow the principles outlined
by the Nippon Storm Registry [18]. Registration for this study will
be administered by the medical staff of each center, who will be
required to complete a hard copy data sheet immediately after
implantation of the cardiac implantable device, to be sent to the
secretary of the JHRS ofﬁce. Cardiac Device Representatives (CDR)
[18] may assist medical staff in record keeping related to cardiac
devices. The JHRS ofﬁce will have access to the JID-CAD website,
and will input patient data according to the prescribed documents.
The JHRS secretary will assign patient-speciﬁc identities (JID-CAD
IDs), which will be shared electronically with the medical staff in
each center. Medical staff may input information on their own
patients into the website via their personal computers. If errors or
inconsistent data are found on a data sheet, the JHRS secretary will
immediately contact the center's medical staff for clariﬁcation.
The follow-up data will be collected by each participating
center every six months for two years after implantation. At the
outpatient clinic, follow-up data will be retrieved from the cardiac
device. Medical staff will input information on their own patients
into the JID-CAD website. To protect patient conﬁdentiality, the
patients' name will not be included in reports, and the JID-CAD ID
only will be used for further analysis. The above method facilitates
data sharing with an independent committee for data
management.
Data collection will commence in October 2014 following
Ethics Committee approval in each center. Patients will be fol-
lowed up for at least two years. Registration of new patients will
be terminated in September 2016. If the target 800 patients are not
recruited by that date, the registration term may be extended,
subject to agreement of central members.
2.4. Data analysis
The primary endpoints of this study are the occurrence of
appropriate therapy, deﬁned as the occurrence of shock therapy or
anti-tachyarrhythmia pacing (ATP) therapy, in patients with ICD
and CRT-D; or the occurrence of sustained ventricular tachycardia
(VT) or ventricular ﬁbrillation (VF) in patients with CRT-P. The
Kaplan–Meier method will be used to estimate the cumulative
probability of death or appropriate therapy at each time point. We
will conduct multivariate analysis using the logistic regression or
Cox proportional hazard model to elucidate factors inﬂuencing the
primary endpoint, such as baseline characteristics or clinical
therapy, including antiarrhythmic and revascularization therapy
for the coronary artery.
Secondary endpoints include time to the occurrence of inap-
propriate therapy, prognosis (death and cause of death, hospita-
lization due to heart failure or other cause) and cardiovascular
events. The Kaplan–Meier method will be also used to estimate
the cumulative probability at each time point. Furthermore, we
will perform multivariate analysis using the logistic regression or
Cox proportional hazard model to elucidate factors inﬂuencing the
time to the occurrence of a secondary endpoint, such as baseline
characteristics or clinical therapy, including antiarrhythmic ther-
apy and revascularization therapy for the coronary artery.
2.5. Deﬁnition of terms
Secondary prevention: A case in which the cardiac implantable
device is implanted for the prevention of sudden cardiac death
from spontaneous sustained ventricular tachycardia (VT) or
ventricular ﬁbrillation (VF), not including VT/VF induced during
electrophysiological testing.
Primary prevention: A case in which the cardiac implantable
device is implanted for the prevention of sudden cardiac death
in a case excluding the abovementioned secondary prevention.
Sustained VT: VT lasting Z30 s, irrespective of ventricular rate
or hemodynamic state; or loss of consciousness during VT, even
where VT lasts o30 s.
Non-sustained VT: Ventricular premature beats lasting
Z6 beats.
In cases with CRT-P, secondary prevention is deﬁned as having
a history of spontaneous VT/VF, and primary prevention as having
no history of spontaneous VT/VF.
2.6. Role of the funding source
The JID-CAD study was organized and supported by the JHRS.
There is no speciﬁc sponsor. The authors have full access to all data
and take full responsibility for study's data integrity, and for the
decision to submit this manuscript for publication.
Table 2
Parameters to be recorded during follow-up observation periods.
1. Date of follow-up
2. Documentation of primary and secondary endpoints
3. Primary endpoint information
(1) Events of VT/VF (nature of therapy and ﬁrst data recording during observation periods, if events occurred more than once)
(2) Clinical background at the occurrence of a primary endpoint (ECG, chest radiograph, blood and laboratory data) and presumed cause of induced VT/VF
(3) Therapy for primary endpoint [admission, vascular reconstruction (PCI, CABG), and therapy for VT/VF (ablation, surgery, change of programming, reoperation of
device, antiarrhythmic agents)]
4. Secondary endpoint
Appropriate therapy (ﬁrst date of administration if events occurred more than once during observation periods)
(1) Death
(2) Admission
(3) Complications related to device implantation (no relation to primary endpoint)
(4) Cardiovascular events not related to device
5. Clinical background not related to primary endpoint
(1) NSVT (base on device memory)
(2) Vascular reconstruction (PCI, surgery)
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3. Discussion
In patients with a history of myocardial infarction and VT, an
ICD can prevent sudden cardiac death and reduce total mortality
[19]. A known history of myocardial infarction can help to estab-
lish the substrate for fatal ventricular tachyarrhythmias, either
acutely or during short-term or long-term follow-up [20]. Regard-
ing the risk of sudden cardiac death after acute myocardial
infarction, typical survival curves demonstrate an initial sharp
decline that plateaus between six and 12 months. In the VALIANT
(Valsartan in Acute Myocardial Infarction) study, for example, the
risk of sudden death was highest in the ﬁrst month after
myocardial infarction (1.4% per month) and subsequently declined
over two years to 0.14% per month [21]. Nevertheless, several
randomized clinical trials have failed to show a survival beneﬁt for
ICDs when implanted early after myocardial infarction in high-risk
patients [22]. Although ICD therapy has been associated with a
reduction in the rate of death due to arrhythmias, this was offset
by an increase in the rate of death from non-arrhythmic causes
[22]. The etiology of the acute myocardial infarction – sudden
cardiac death paradox is unclear, but may be related to the
changing nature of the substrate over a period of several months
after acute myocardial infarction [22]. Further investigation is
needed to explain the actual causes of death in the early post-
myocardial infarction period, and to ﬁnd which interventions can
be applied to reduce the increased rate of sudden death [20].
Limited data exist concerning the long-term incidence and
prognosis of heart failure after myocardial infarction, particularly
in the era of coronary revascularization. New-onset heart failure
signiﬁcantly increases the mortality risk among these patients
[23]. Current ICD trials have shown that the time from shock to a
heart failure event ranges from 160 to 204 days, depending on the
number of appropriate or inappropriate shocks and the etiology of
heart failure [24]. Patients with chronic CAD who are treated with
ICDs have improved survival rates but an increased risk of heart
failure [25]. Thus, heart failure patients with an ICD shock are at
increased risk of heart failure-related hospitalization and heart
failure events [26,27].
In addition to triggering heart failure, ICD shocks are painful,
and furthermore do not provide complete protection against
sudden cardiac death [28]. Prophylactic and therapeutic VT abla-
tion appear to prolong the time to recurrence of VT or a rapid rate
of non-sustained VT in patients with stable VT, previous myocar-
dial infarction, and reduced left ventricular ejection fraction
(LVEF) [19,29]. In the Surgical Treatment for Ischemic Heart
Failure (STICH) trial, patients with CAD and an EFZ35% were
randomized to receive either a coronary artery bypass graft
(CABG) or medical therapy. There was no interaction between
ischemia and treatment for any clinical endpoint [30]. In CAD
with severe LV dysfunction, inducible myocardial ischemia does
not identify patients with worse prognosis, or those that could
beneﬁt from CABG over optimal medical therapy [30]. Thus, it is
largely unknown whether revascularization therapy attenuates
infrequent VT, or inﬂuences appropriate ICD shock in Japanese
patients.
The previous multinational study [31] showed variation across
countries in readmission rates, mortality, and outcome after
myocardial infarction. This may have resulted from differences in
health-care policy, quality of health systems and clinical practice.
These factors could account for differences in appropriate device
therapy, and hospitalization and mortality rates in Japan, which
have not yet been determined. Therefore, in this study, we will
elucidate the current status of appropriate device therapy in CAD
patients implanted with a cardiac device, and evaluate how
appropriate therapy is inﬂuenced by catheter ablation and
revascularization.
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